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Platelet-derived growth factor (PDGF) has been proved to
play an important role in progressive glomerular disease of
systemic lupus. The present study investigated the tyrosine
kinase inhibitor of PDGF receptor, imatinib, as a novel
therapeutic approach for the cure of lupus nephritis in New
Zealand Black/White (NZB/W)F1 hybrid mice with established
disease. Two groups of NZB/W mice (N¼ 30 each group),
starting at 5 months of age, were given by gavage vehicle or
imatinib (50 mg/kg b.i.d). Fifteen mice for each group were
used for the survival study. The remaining were killed at 8
months. Imatinib significantly (P¼ 0.0022) ameliorated
animal survival with respect to vehicle. The drug significantly
delayed the onset of proteinuria (% proteinuric mice, 7 and 8
months: 33 and 47 vs vehicle, 80 and 87, Po0.05) and
limited the impairment of renal function. Imatinib protected
the kidney against glomerular hypercellularity and
deposits, tubulointerstitial damage, and accumulation of
F4/80-positive mononuclear cells and a-smooth actin-positive
myofibroblasts. The abnormal transforming growth factor-b
mRNA expression in kidneys of lupus mice was reduced by
imatinib. In conclusion, findings of amelioration of animal
survival and renal manifestations in NZB/W lupus mice with
established disease by imatinib suggests the possibility to
explore whether imatinib may function as steroid-sparing
drug in human lupus nephritis.
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New Zealand Black/White (NZB/W)F1 hybrid mice sponta-
neously develop an autoimmune disease with immune
complex glomerulonephritis, proteinuria, and progression
to renal insufficiency, reminiscent of human systemic lupus
erythematosus.1,2 Although many different immunologic
and nonimmunologic factors contribute to disease expression
in lupus nephritis, the production of autoantibodies
against nuclear and endogenous antigens and the formation
of glomerular immune deposits are typically initial events.3
Factors leading to autoantibody production include break-
down of B- and T-cell tolerance, defects in removal of
apoptotic cells, and abnormal presentation of autoantigens
(e.g., nucleosomes, DNA complexed to histones).4,5 Immune
deposits seem to form in situ through the direct binding
of autoantibodies to intrinsic constituents of the glomerular
basement membrane or to glomerular cells,3 resulting
in complement activation and recruitment of inflammatory
cells, along with activation of renal parenchymal cells. Cyto-
kines and chemoattractants generated by renal resident and
infiltrating cells amplify and perpetuate immune complex-
mediated injury. Therapies include immunosuppressants to
reduce immune complexes, associated with steroids6 that
potently limit upregulation of cytokines and chemokines
in activated cells.7 Both categories of drugs, however,
cause significant side –effects, including susceptibility to
infection and cancer.8,9 This has resulted in a quest to identify
less toxic drugs to modulate immune complex formation
and deposition, as well as molecules directed against the
inflammatory reaction.10–15
Overproduction of platelet-derived growth factor (PDGF),
particularly the PDGF-B isoform, has been consistently
implicated in the cell proliferation and extracellular matrix
accumulation that characterize progressive inflammatory
glomerular disease of systemic lupus.16–18 Elevated levels of
PDGF-B chain mRNA were found in the kidneys of both
NZB/W19,20 and MRL-lpr21 lupus mice as well as of patients
with lupus nephritis,22 in correlation with the progression of
the nephritis. PDGFs are a pleiotropic group of peptide
growth factors that can be synthesized both by inflammatory
cells and resident renal cells.16,17 Biological effects of PDGF
include promotion of cell proliferation and extracellular
matrix synthesis, chemotaxis, modulation of synthesis of
various growth factors, and regulation of inflammatory
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responses. PDGF isoforms signal through cell surface
PDGF receptor tyrosine kinase, the a- and b-receptors, with
different affinities.17 Ligand binding induces receptor dimer-
ization and autophosphorylation, leading to activation of
cytoplasmic SH2 domain-containing signal transduction
molecules, thereby initiating various signaling pathways,
including tyrosine phosphorylation and c-fos mRNA induc-
tion. There are different potential strategies to block PDGF
overactivity. The administration of neutralizing anti-
bodies or oligonucleotide aptamer antagonist against PDGF
ameliorated experimental glomerulonephritis.23,24 Mono-
clonal PDGF receptor antibodies that block ligand binding
and receptor activation have also been described.17 However,
these maneuvers remain an uncertain possibility for human
use. Inhibitors of PDGF receptor tyrosine kinases have been
developed more recently. Imatinib mesylate (Glivec, formerly
known as STI571), a 2-phenylaminopyrimidine derivative, is
a selective inhibitor of the tyrosine kinases ABL, PDGF
receptors, and c-kit.25,26 Because of its capacity to block BCR-
ABL oncoprotein, it is used clinically in chronic myeloid
leukemia.26 Imatinib has been reported to prevent experi-
mental mesangial proliferative glomerulonephritis27 and to
confer renoprotection in a model of accelerated diabetic
nephropathy.28
In the present study, we sought to investigate whether the
use of imatinib may represent a new therapeutic approach to
lupus nephritis. Specifically, we evaluated whether imatinib
could mitigate established renal disease and prolong survival
of NZB/W lupus mice possibly by virtue of the drug’s
antiproliferative and antifibrogenic actions.
RESULTS
NZB/W mice treated with imatinib gained weight in a
manner similar to that of mice given vehicle (at 8 months of
age, body weight: 3470.8 vs 3370.5 g). There were no signs
of liver dysfunction in treated mice as indicated by levels of
serum aspartate aminotransferase and alanine aminotrans-
ferase similar to vehicle-mice (at 8 months of age, aspartate
aminotransferase: 15278 vs 151712 UI/l; alanine amino-
transferase: 2571 vs 2373 UI/l).
Imatinib ameliorates survival of NZB/W lupus mice
Figure 1 shows the survival curves of NZB/W mice given
vehicle or imatinib from 5 months of age. Mice treated with
imatinib survived significantly longer than vehicle-mice
(P¼ 0.0022). The mean time to death was 9.5 vs 8.3 months,
respectively. At 8 months of age, 100% of mice given the drug
were alive as compared with 53% of those on vehicle. At 10
months, when all mice died in the vehicle group, the
percentage of survival for imatinib group was 20%.
Effect of imatinib on proteinuria and renal function
Cumulative percentage of mice with heavy proteinuria
(44 mg/day) was evaluated at different stages of the disease
in the two experimental groups. As shown in Figure 2,
imatinib significantly delayed the onset of proteinuria as
compared to vehicle. Thus, at 7 and 8 months of age, the
percentage of proteinuric mice was 33 and 47% in the treated
group vs 80 and 87% in the vehicle-group (Po0.05). At 9
months, the percentage of proteinuric mice in the two groups
increased to 86 and 100%, respectively.
Basal levels of blood urea nitrogen (BUN) as determined
in all mice at 2 months of age wereo30 mg/dl. Table 1 shows
the percentage of vehicle or imatinib-treated lupus mice
with abnormal BUN levels, that is, 430 mg/dl, during the
experimental period. In the vehicle group, renal function
progressively deteriorated so that at 7, 8, and 9 months of
age, 67, 88, and 100% of lupus mice, respectively, had
abnormal BUN values. By contrast, in the imatinib group,
percentages reached only 27% (7 months) and 47% (8
and 9 months).
Effect of imatinib on anti-DNA antibodies
Serum levels of circulating anti-DNA antibodies measured
in 2-month-old NZB/W mice averaged 1071.4 U/ml. Anti-
DNA antibodies significantly increased during time averaging
144761 U/ml at 5 months of age, before treatment, and
reaching 2707125 U/ml at 8 months in NZB/W mice given
vehicle (Po0.01 and Po0.001 vs 2 months, respectively). In
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Figure 1 | Survival rate in NZB/W mice orally given imatinib
(50 mg/kg b.i.d) or vehicle from 5 months of age, a time point
that follows the onset of immune complex deposition. Imatinib
significantly (P¼ 0.0022) prolonged life survival.
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Figure 2 | Effect of imatinib on the cumulative percentage of mice
with proteinuria 44 mg/day in NZB/W mice at different months
of age. Treatment started at 5 months of age. Each point reflects the
current level of proteinuria in surviving mice as well as the last
measurement in deceased mice. *Po0.05 vs vehicle.
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mice treated with imatinib, anti-DNA formation was slightly
retarded (203792 U/ml).
Effect of imatinib on renal histology
By light microscopy, focal glomerular hypercellularity was
found in the kidneys of mice killed at 5 months of age, time at
which the treatment was started (score 0.670.2). By immuno-
fluorescence, immunoglobulin G (IgG) and complement 3
(C3) deposits were found in glomeruli with predominant
mesangial distribution (Figure 3). The presence of immune
complex disease was confirmed by electron microscopy
analysis showing both mesangial and subendothelial electron
dense deposits (Figure 3). No or very sparse glomerular
deposits of IgG and C3 nor glomerular electron dense deposits
were detected in 2-month-old NZB/W mice (Figure 3).
As shown in Table 2, at 8 months, NZB/W mice given
vehicle revealed glomerular changes consisting of intracapil-
lary hypercellularity associated with focal extracapillary
proliferation. Immune-type deposits were detected in the
mesangium and in the glomerular capillary walls with
subendothelial distribution. Tubular damage, interstitial
inflammation, and fibrosis were present. Treatment with
imatinib limited glomerular hypercellularity, deposits, and
tubulointerstitial damage (Po0.05 vs vehicle) (Table 2).
At 8 months, in vehicle-treated mice, there were diffuse
granular deposits of IgG and C3 in the mesangium and in the
glomerular capillary wall. In mice treated with imatinib, less
IgG and C3 deposits were detected than that of mice treated
with vehicle, but a statistical significance was not reached
(score, IgG: 1.8070.16 vs 2.2770.13; C3: 1.6070.19 vs
2.2170.21).
Imatinib limits renal inflammation and myofibroblast
accumulation
A marked accumulation of F4/80-positive monocytes/
macrophages was present in the renal interstitium of NZB/
W mice given vehicle (8576 vs CD-1 control mice: 471
cells/high-power field (HPF), Po0.01). Treatment with
imatinib significantly (Po0.01) reduced peritubular F4/80-
positive cell accumulation (4578 cells/HPF) (Figure 4).
Infiltrates of monocytes/macrophages were also observed at
periglomerular level in vehicle-mice (1372 cells/HPF vs
controls, 0.970.2 cells/HPF, Po0.01), and were limited by
the drug (672 cells/HPF, Po0.05 vs vehicle) (Figure 4).
In control kidneys, interstitial immunostaining for
a-smooth muscle actin (a-SMA) was present only in
sparse cells (score, 0.3570.12). In the kidneys of lupus
mice given vehicle, the interstitial expression of a-SMA was
markedly increased (score, 2.0670.05). This increase was
significantly (Po0.05) prevented by imatinib (score,
1.3770.23) (Figure 5).
As to the mechanism underlying imatinib’s effect on the
accumulation of a-SMA-positive cells, we have analyzed
the expression of transforming growth factor-b (TGF-b), a
strong stimulus for the differentiation of fibroblasts and
other cell types to a-SMA-positive myofibroblasts. Real-time
polymerase chain reaction (PCR) analysis showed that TGF-b
mRNA levels were increased in the kidneys of NZB/W mice
given vehicle (fourfold increase over CD-1 control mice).
Cytokine upregulation was significantly (Po0.05) reduced by
Table 1 | Cumulative % mice with BUN430 mg/dl
Months of age 2 6 7 8 9 10
Vehicle (%) 0 27 67 88 100 100
Imatinib (%) 0 0 27 47 47 53
BUN, blood urea nitrogen.
BUN levels430 mg/dl were considered abnormal (normal range: 14–29 mg/dl).
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Figure 3 | Evidence of established immune complex deposition in
glomeruli at the time at which imatinib treatment is started.
Representative sections of glomeruli of (left panels) 2-month-old
NZB/W mice, and (right panels) 5-month-old NZB/W mice studied at
the time at which the treatment with imatinib started, stained by
immunofluorescence for (a, b) IgG and (c, d) C3, or (e, f) analyzed by
electron microscopy. Arrows in (f) indicate electron dense immune
deposits.
Table 2 | Effect of imatinib treatment on renal histology in
NZB/W mice
Glomeruli
Tubulo-interstitial
damage
Intracapillary
hypercellularity
(score)
Extracapillary
hypercellularity
(score)
Deposits
(score) (score)
Vehicle 2.1370.13 2.570.3 2.170.2 1.3070.1
Imatinib 1.3370.22* 1.570.3* 1.270.3* 0.7570.1*
NZB/W, New Zealand Black/White.
Data are mean7s.e. *Po0.05 vs vehicle.
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imatinib, to the extent that in treated mice, renal TGF-b
expression increased by only twofold over controls.
DISCUSSION
In the present study, we have investigated the tyrosine kinase
inhibitor imatinib as a novel therapeutic option for the cure
of lupus nephritis. The drug retarded the evolution of renal
disease of NZB/W lupus mice and ameliorated survival as
compared to untreated animals. Specifically, imatinib orally
administered after the onset of immune complex deposition
delayed the development of proteinuria to a significant
extent, prevented renal function impairment, and limited
glomerular hypercellularity, immune type deposits, tubular
damage, and interstitial inflammation and fibrosis. These
effects were associated with lower levels of circulating anti-
DNA antibodies with respect to NZB/W mice given vehicle.
Imatinib has been originally developed as a therapeutic
agent for chronic myeloid leukemia.25,26 By inhibiting BCR-
ABL tyrosine kinase, it targets the molecular event implicated
as the direct cause of the disease. Although highly specific,
imatinib occupies the adenosine triphosphate-binding site of
several tyrosine kinase molecules such as ABL, ABL-related
gene product, the PDGF receptor, and the stem cell factor
receptor c-kit, impeding the ensuing signal transduction.26
Clinical trials in chronic myeloid leukemia showed that the
drug produced an unprecedented rate of hematologic and
cytogenetic remission.26 Moreover, imatinib yielded encoura-
ging results in patients with gastrointestinal stroma tumors
caused by c-kit mutations and myeloproliferative disorders
with rearrangements of PDGF receptor, diseases where the
activation of an imatinib-sensitive kinase is central to the
pathogenesis.29–31
The inhibitory effect of imatinib on PDGF receptor
activation suggested its potential application to nonmalig-
nant diseases in which PDGF has been strongly implicated,
such as glomerulonephritis. Imatinib ameliorated experi-
mental mesangial proliferative glomerulonephritis causing
significant reductions in mesangial cell proliferation, num-
bers of activated/a-SMA-positive mesangial cells and extra-
cellular matrix accumulation.27 Renoprotective effects of
imatinib have been recently reported against the diabetic
nephropathy of apolipoprotein E-knockout mice, a model of
accelerated renal disease associated with increased renal
expression of PDGF-B.28 The drug administered starting
immediately after diabetes induction for 20 weeks reduced
albuminuria and limited glomerular changes. Tubulointer-
stitial inflammation and fibrosis were also attenuated by the
treatment. Protective effects achieved in NZB/W lupus mice
by interrupting PDGF signal transduction with imatinib,
while emphasizing the role of PDGF in the manifestation of
the disease, suggest the PDGF pathway as a therapeutic target
in lupus nephritis. Experimental studies showed progressively
increasing PDGF mRNA expression in the renal cortex of
lupus mice during the evolution of the disease.19,21 Moreover,
in renal tissue from patients with diffuse proliferative lupus
nephritis, gene and protein expression of both PDGF-B chain
and PDGF-b receptor increased in correlation with the
histologic grade. Sites of localization were the mesangium,
cells of the capillary walls, crescents, and mononuclear cells
infiltrating the interstitium.22 In the current study, PDGF-
receptor tyrosine kinase inhibition was associated with
reduced accumulation of monocytes/macrophages in the
kidneys, suggesting that PDGF may contribute, together with
other cytokines,32 to inflammatory cell influx into the kidney
in lupus nephritis. A chemotactic activity of PDGF on
monocytes as well as granulocytes and fibroblasts has been
documented in vitro.33 Another significant finding here
was the reduction after imatinib of a-SMA-positive myo-
fibroblasts in the renal interstitium. This could be either the
result of a direct effect on PDGF, known to induce
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Figure 4 | F4/80-positive monocytes/macrophages infiltrating the
kidney of NZB/W mice and the effect of imatinib. Data are
mean7s.e. HPF, high-power field. **Po0.01 vs vehicle. Original
magnification  400.
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Figure 5 | Accumulation of a-smooth muscle actin (SMA)-positive
cells in the renal interstitium of NZB/W mice is reduced by
imatinib. Data are mean7s.e. *Po0.05 vs vehicle. Original
magnification  400.
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transdifferentiation of renal fibroblasts into a-SMA-positive
myofibroblasts,34 or involve other profibrotic factors such
as TGF-b, activated through PDGF receptor-dependent
pathways.28,35 Our data showing that the overexpression of
TGF-b mRNA in the kidneys of lupus mice was decreased
by imatinib are in line with findings of reduced expression
of TGF-b in the glomeruli and the tubulointerstitium after
treatment with the drug in diabetic mice.28 On the other
hand, the antifibrotic effect afforded by imatinib could be
related to the fact that TGF-b may directly signal through the
c-ABL tyrosine kinase, a target of imatinib. Thus, in cultured
fibroblasts, TGF-b directly stimulated c-ABL activity, in-
dependently of Smad 2/3 phosphorylation or PDGF receptor
activation, and the inhibition of c-ABL by imatinib prevented
TGF-b-induced morphologic transformation and extracellu-
lar matrix gene expression.36 Finally, in a mouse model of
bleomycin-induced pulmonary fibrosis, treatment with im-
atinib was found to prevent cytokine-induced lung fibrosis.36
The finding that imatinib treatment slightly retarded anti-
DNA antibody formation as compared to vehicle reflects the
immunoregulatory potential of the drug in NZB/W mice.
Consistent with this possibility, imatinib delayed to some
extent immune complex deposition as suggested by less
glomerular IgG and C3 staining, thereby resulting in the
attenuation of the downstream disease. In vitro studies have
shown that imatinib, at concentrations achieved in vivo,
inhibited the proliferation37 and activation38 of T cells via
inhibition of early signaling mediated by the T-cell receptor.39
Consistently with inhibition on T-cell activation, it was
found that imatinib reduced IL-2 production by activated
T cells.39 Moreover, that imatinib may affect the T-cell
response in vivo rests on the observation that imatinib
inhibited delayed-type hypersensitivity in mice.37 Mechanisms
by which imatinib might modulate T- and B-cell-mediated
pathogenic pathways in lupus nephritis are beyond the scope
of the present paper and merit to be investigated further.
In conclusion, this study documents the effect of tyrosine
kinase inhibition with imatinib in attenuating renal mani-
festations and prolonging survival in NZB/W lupus mice
with established disease. These results imply the need to
assess whether imatinib may function as steroid-sparing drug
in human lupus nephritis.
MATERIALS AND METHODS
Experimental design
NZB/W F1 female mice, 2 months of age, were obtained from
Harlan Italy s.r.l., Milano, Italy. Animal care and treatment were
conducted in conformity with the institutional guidelines that are in
compliance with national (Decreto Legislativo n.116, Gazzetta
Ufficiale suppl 40, 18 febbraio 1992, Circolare n.8, Gazzetta Ufficiale
14 luglio 1994) and international laws and policies (EEC Council
Directive 86/609, OJL358-1, December 1987; Guide for the Care and
Use of Laboratory Animals, US National Research Council, 1996).
Animals were housed in a constant temperature room with a 12-h
dark/12-h light cycle and fed a standard diet. Lupus mice were
allocated to the following groups. Group 1 (n¼ 30) was given the
drug vehicle (water) by gavage; Group 2 (n¼ 30) was given imatinib
mesylate/Glivec (Novartis Pharma AG, Basel, Switzerland) by gavage
at the dose of 50 mg/kg b.i.d./day. Treatment started at 5 months of
age. Fifteen animals for each group were used for survival studies.
The others were killed at 8 months. Five NZB/W mice were killed
at 2 months of age. Five normal CD-1 mice (Charles River Italia,
Calco, Italy) were killed at 8 months and used as controls.
Five additional NZB/W mice were killed at 5 months of age to
confirm that in the present cohort of mice, immune complex
deposition occurs at the time at which imatinib treatment is
started. Immunofluorescence and electron microscopy studies
were performed in comparison with the kidneys taken from
2-month-old NZB/W mice.
Urinary protein excretion was measured at 5 months (baseline)
and every 2 weeks. Levels 44 mg/day were considered abnormal.
Serum BUN was evaluated monthly. At the time of killing, blood
was collected for measurements of serum anti-DNA antibodies and
transaminase (aspartate aminotransferase, alanine aminotransfer-
ase). The kidneys were processed for histological analysis by
light microscopy. Renal TGF-b mRNA expression was evaluated
by real-time PCR.
Proteinuria and renal function
Urinary protein concentration was determined by the Coomassie
blue G dye-binding assay with bovine serum albumin as
standard. Renal function was assessed as BUN in heparinized blood
by the Reflotron test (Roche Diagnostics Corporation, Indianapolis,
IN, USA).
Anti-DNA antibodies
Serum levels of anti-dsDNA autoantibodies were evaluated by
enzyme immunoassay (Diastat anti-ds DNA kit, Bouty Laboratory,
Milano, Italy) as described before.13
Serum transaminase
Serum levels of aspartate aminotransferase and alanine amino-
transferase were measured using the Reflotron test (Roche
Diagnostics Corporation).
Renal morphology
Light microscopy. Fragments of renal cortex were fixed in
Duboscq-Brazil, dehydrated in alcohol, and embedded in paraffin.
Sections (3mm) were stained with hematoxylin and eosin, Masson’s
trichrome, and periodic acid-Schiff ’s reagent stain. Glomerular
intracapillary hypercellularity was given a score ranging from
0 to 3þ (0¼ no hypercellularity; 1þ ¼mild; 2þ ¼moderate;
3þ ¼ severe). Extracapillary proliferation was graded from 0 to 3þ
(0¼ no hypercellularity; 1þ ¼ less than 25% of glomeruli involved;
2þ ¼ 25–50% of glomeruli involved; 3þ ¼more than 50% of
glomeruli involved). Deposits were graded from 0 to 3þ (0¼ no
deposits; 1þ ¼ less than 25% of glomeruli involved; 2þ ¼ 25–50%
of glomeruli involved; 3þ ¼more than 50% of glomeruli
involved). At least 100 glomeruli were examined for each biopsy.
Tubular (atrophy, casts, and dilatation) and interstitial changes
(fibrosis and inflammation) were graded from 0 to 3þ (0¼ no
changes; 1þ ¼ changes affecting less than 25% of the sample;
2þ ¼ changes affecting 25–50% of the sample; 3þ ¼ changes
affecting more than 50% of the sample).32 At least 10 fields per
sample were examined at low magnification ( 10) for scoring of
the interstitium. Biopsies were analyzed by the same pathologist, in
a single-blind fashion.
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Immunofluorescence. Studies were performed on frozen tissue
embedded in 22-oxacalcitriol. Sections of 3 mm were cut, fixed in
acetone, washed with phosphate buffer saline pH 7.4 for 10 min,
blocked with phosphate-buffered saline/1% bovine serum albumin
for 15 min, and stained with fluorescein isothiocyanate-conjugated
antibodies to mouse IgG (Sigma-Aldrich, St Louis, MO, USA)
or C3 (NL Cappel Laboratories Inc., West Chester, PA, USA).
Glomerular staining intensity was graded from 0 to 3þ (0¼ no
staining; 1þ ¼ faint staining; 2þ ¼ intense staining; 3þ ¼ very
intense staining).
Electron microscopy. Fragments of cortical kidney tissue from
2-month-old and 5-month-old NZB/W mice were fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, overnight
at 41C, and washed repeatedly in cacodylate buffer. After post-
fixation in 1% OsO4 for 1 h, specimens were dehydrated through
ascending grades of alcohol and embedded in Epon resin. Ultrathin
sections were stained with uranyl acetate for examination using a
Philips Morgagni transmission electron microscope.
Immunohistochemical analysis
F4/80-positive cells. Paraffin sections (3 mm) were dewaxed
and taken through graded alcohols. Rat monoclonal antibody
against a cytoplasmic antigen of mouse monocytes and macro-
phages (F4/80, 2.5 mg/ml, Caltag Laboratories, Burlingame, CA,
USA) was used for detection of infiltrating cells. Sections were
incubated for 30 min with 0.3% H2O2 in methanol to quench
endogenous peroxidase. The tissue was permeabilized in 0.1%
Triton X-100 in phosphate-buffered saline 0.01 mol/l, pH 7.2, for
30 min and then incubated with 2% normal goat serum (Vector
Laboratories, Burlingame, CA, USA) for 30 min. Primary antibody
was incubated overnight at 41C, followed by the secondary antibody
(biotinylated goat anti-rat IgG, Vector Laboratories) and avidin–-
biotin peroxidase complex solution, and finally development with
diaminobenzidine. The sections were counterstained with Harris
hematoxylin. Negative controls were obtained by omitting the
primary antibody. F4/80-labeled cells were counted in 20 randomly
selected high-power microscopic fields ( 400) per each animal.
a-SMA-positive cells. Tissue specimens were embedded in 22-
oxacalcitriol medium and frozen in liquid nitrogen. Tissue sections
were cut at 3 mm using a Mikrom 500 O cryostat (Mikrom, Walldorf,
Germany) and either stained immediately or stored at 801C. Non-
specific binding of antibodies was blocked with phosphate-buffered
saline/1% bovine serum albumin for 15 min (room temperature).
Sections were incubated for direct immunofluorescence using a Cy3-
conjugated monoclonal anti-a-SMA antibody (1A4, purified mouse
IgG, 1:200, Sigma Co., St Louis, MO, USA) for 1 h at room
temperature. For the evaluation of immunofluorescence staining,
randomly selected, consecutive fields of view (at least 20 in each
section,  400) were examined by an investigator without the
knowledge of the experimental group. The staining for a-SMA was
assessed semiquantitatively assigning a score for each field as follows:
0, no staining; 1þ , mild (up to 25% of interstitial area); 2þ ,
moderate (425–50%); 3þ , marked accumulation of a-SMA cells
(450% of the interstitial area). The mean values were calculated for
each specimen and used for statistical analysis.
Renal expression of TGF-b mRNA
Total RNA was isolated from whole kidney tissue by using TRIzol
Reagent (Invitrogen, San Giuliano milanese, Italy). Contaminating
genomic DNA was removed by RNase-free DNase (Promega,
Ingelheim, Germany) for 1 h at 371C. Purified RNA (2mg) was
reverse transcribed using random examers (50 ng) and 200 U of
SuperScript II RT (Life Technologies, San Giuliano Milanese, Italy)
for 1 h at 421C. No enzyme was added for reverse transcriptase-
negative controls.
Real-time PCR was performed with ABI PRISM 5700 Sequence
Detection System (PE Biosystems, Warrington, UK) using SYBR
GREEN PCR Master Mix (PE biosystems). After an initial hold of
2 min at 501C and 10 min at 951C, the samples were cycled 40 times
at 951C for 15 s and 601C for 60 s. Fluorescent detection, defined as
threshold cycle (Ct), is picked in exponential phase of PCR and used
for relative quantification of target gene. The comparative Ct
method normalizes the number of target gene copies to an
endogenous control gene as 18S (DCt). Gene expression was then
evaluated by a quantification of a cDNA corresponding with the
target gene relative to a calibrator serving as physiologic reference
(e.g. control group, DDCt). On the basis of exponential amplifica-
tion of target gene as well as calibrator, the amount of amplified
molecules at the threshold cycle is given by: 2ðDDCtÞ:
The following specific primers were used: mouse TGF-b1
(300 nM): forward 50-GCTGAACCAAGGAGACGGAAT-30, reverse
50-AAGAGCAGTGAGCGCTGAATC-30; 18S (50 nM): forward 50-AC
GGCTACCACATCCAAGGA-30, reverse 50-CGGGAGTGGGTAATTT
GCG-30.
Statistical analysis
Data are expressed as mean7s.e. The time occurrence of death was
assessed by Kaplan–Meier cumulative survival functions. Time-to-
event (death) was calculated in months. Survival distribution
between the two groups (i.e. vehicle vs imatinib) was compared
by log-rank test. Proteinuria data were analyzed by Fisher’s exact
test. All the other parameters were analyzed by Kruskall Wallis or
Mann–Whitney U-test as appropriate. Statistical significance was
defined as Po0.05.
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autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum
2005; 52: 3987–3996.
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